Therapeutics Targeting the Core Apoptotic Machinery
Open accessThe DOI matches its Crossref record; 181 of the 185 references it cites were found in a registry or an index.
Abstract
Therapeutic targeting of the apoptotic pathways for the treatment of cancer is emerging as a valid and exciting approach in anti-cancer therapeutics. Accumulating evidence demonstrates that cancer cells are typically “addicted” to a small number of anti-apoptotic proteins for their survival, and direct targeting of these proteins could provide valuable approaches for directly killing cancer cells. Several approaches and agents are in clinical development targeting either the intrinsic mitochondrial apoptotic pathway or the extrinsic death receptor mediated pathways. In this review, we discuss the main apoptosis pathways and the key molecular targets which are the subject of several drug development approaches, the clinical development of these agents and the emerging resistance factors and combinatorial treatment approaches for this class of agents with existing and emerging novel targeted anti-cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Targeting the apoptotic core machinery, including BCL-2 family proteins, inhibitors of apoptosis proteins (IAPs), death receptors, and caspases, can promote cancer cell death and reduce resistance [52].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [52]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Resisting cell death is an important hallmark of cancer cells and a key contributor to therapy resistance in CRC.”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Resistance to apoptotic cell death is a recognized hallmark of cancer, making the molecular drivers of the anti-apoptotic response appealing anti-cancer therapeutic targets [1,2].”
BackgroundHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680 · cited 2×
“Both pathways are well described and tightly regulated by a family of cysteine proteases known as the caspases [4].”
BackgroundCancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 1×
“However, accumulating evidence suggests that rather than losing the effectors of apoptosis, many cancer cells enhance expression of a relatively small number of anti-apoptotic proteins and become “addicted” to these proteins for their survival [16]; therefore, direct targeting of these proteins provides valuable avenu…”
BackgroundSelf-citationAn inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219 · cited 17×
“AMG-176 was the first MCL-1 specific inhibitor to enter clinical trial (NCT03797261) closely followed by AZD5991[60–62].”
BackgroundInfluentialBcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells
Vaux, D. L., Cory, S., & Adams, J. M. (1988) · Nature · doi:10.1038/335440a0 · Cited by 3,219
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058 · cited 3×
“gov indicates over 250 active trials in cancer with venetoclax both as monotherapy and in combination with standard-of-care and other novel targeted agents to tackle the emerging resistance [26].”
BackgroundIdentification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900 · cited 1×
“Early studies with tumor necrosis factor (TNF) and agents targeting the Fas (CD‐ 95/Apo‐1) death receptor were halted due to dose‐limiting toxicities in clinical trials [129,130].”
BackgroundMitochondria as multifaceted regulators of cell death
Bock, F. J., & Tait, S. W. G. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0173-8 · Cited by 2,450
Research works printed but not linked: 1
- (2019, September 12). Amgen News Release. Available online: https://www.amgen.com/newsroom/press-releases/2019/09/amgen-highlights-new-data-from-kyprolis-carfilzomib-and-oncology-pipeline-at-imw-2019.
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Resisting cell death is an important hallmark of cancer cells and a key contributor to therapy resistance in CRC. Apoptosis is a non-lytic form of programmed cell death (type I) and is the primary mechanism by which therapies use to eliminate cancer cells [52].”
Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer
Westaby, D., Jiménez‐Vacas, J. M., Padilha, A., Varkaris, A. S., Balk, S. P., Bono, J. S. D., & Sharp, A. (2021) · Cancers · doi:10.3390/cancers14010051 · Cited by 67
Cell death in cancer chemotherapy using taxanes
Xu, A. P., Xu, L. B., Smith, E. R., Fleishman, J. S., Chen, Z., & Xu, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1338633 · Cited by 41
“…escape programmed cell death, and both apoptotic and necroptotic pathways are de-sensitized in the processes of transformation (Igney and Krammer, 2002; Mohammad et al., 2015; Campbell and Leung, 2021; Hamilton et al., 2021; Neophytou et al., 2021; Hagenbourger et al., 2022; Zehnle et al., 2022).”
BackgroundWawszczyk, J., Jesse, K., & Kapral, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021115 · Cited by 17
“Most anticancer drugs exert their biological activity by inhibition of the cell cycle and induction of programmed cell death, such as apoptosis, autophagy, and necroptosis [7,8].”
BackgroundInfluentialHuang, Q., Wang, X. R., Chen, A., Zhang, H., Yu, Q., Shen, C., Awadasseid, A., Zhao, X., Xiong, X., Wu, Y., et al. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115062 · Cited by 16
Metadata
- Authors
- Hamilton, C., Fox, J. P., Longley, D. B., & Higgins, C. A.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Higgins, Catherine A.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-05-26
- Volume
- 13
- Issue
- 11
- Pages
- 2618
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC8198123
- OpenAlex
- W3164877207
- Cited by
- 26
- References
- 185
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 2 · 2023: 5 · 2022: 5 · 2021: 3
- FWCI
- 0.39
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-05-26)
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Wellcome Trust (110371/Z/15/Z)
- Cancer Research UK (24387)
- Medical Research Council (MR/S021205/1)
- Biotechnology and Biological Sciences Research Council (BB/T002824/1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pharmacology (medical) › Flavonoids in Medical Research
- Keywords
- apoptosis, cancer therapy, anti-apoptotic proteins, intrinsic mitochondrial apoptotic pathway, extrinsic death receptor pathway, targeted cancer therapy, drug resistance, combination therapy, clinical development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutics Targeting the Core Apoptotic Machinery. https://app.cochat.ai/papers/10.3390/cancers13112618
- The paper
- Hamilton, C., Fox, J. P., Longley, D. B., & Higgins, C. A. (2021). Therapeutics Targeting the Core Apoptotic Machinery. Cancers. https://doi.org/10.3390/cancers13112618
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.